|
Prolastin® Home
Contact Talecris
General Conditions of Use
Privacy Statement
Contact Prolastin®
About Prolastin®
Safety & Tolerability
Efficacy
Dosing
Convenience
Commitment to Patients with AAT Deficiency
Understanding AAT Deficiency
Clinical Manifestations
AAT Deficiency-Associated Liver Disease
AAT Deficiency Diagnosis & Treatment
Testing Recommendations
Testing for AAT Deficiency
AAT Test Kit
Treatment Options
Prolastin Clinical Data
German Registry
NHLSI Registry
Prolastin Direct
Tools & Resources
Patient Support
Patient Tools
AAT Deficiency Classic Research
Dosing Calculator
Request Materials
Online Resources
Prescribing Information
Patients/Caregivers
Important Safety Information
Prolastin®, Alpha1-Proteinase Inhibitor (Human) is indicated for chronic replacement therapy of individuals having congenital deficiency of alpha-1 PI (alpha1-antitrypsin deficiency) with clinically demonstrable panacinar emphysema. Weekly Prolastin® therapy has demonstrated a low occurrence of side effects. In clinical studies with Prolastin®, reactions were observed in 1.16% of infusions, the most common events being fever (0.77%), light-headedness (0.19%), and dizziness (0.19%). As with all plasma-derived therapeutics, the potential to transmit infectious agents cannot be totally eliminated. Individuals with selective IgA deficiencies who have known antibody against IgA (anti-IgA antibody) should not receive Prolastin®, since these patients may experience severe reactions, including anaphylaxis, to IgA which may be present.
You are encouraged to report negative side effects of prescription drugs
to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.
Please click here for Prolastin® full Prescribing Information.
Remember, your doctor or healthcare provider is the single best source of information regarding you and your health. Please consult your doctor or healthcare provider if you have any questions about your health or any of your medications.
|